CALCITONIN PRODUCTS AND THERAPIES FOR TREATING INFLAMMATORY OR DEGENERATIVE DISEASES
Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject.
1 . A method for treating a degenerative or an inflammatory disease in a subject comprising:
administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and
co-administering, as part of a combination therapy, a therapeutically effective amount of a matrix metalloproteinase inhibitor to the subject.
2 . The method of claim 1 wherein the calcitonin is selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin and elcatonin.
3 . The method of claim 1 wherein the calcitonin is salmon calcitonin.
4 . The method of claim 1 wherein the matrix metalloproteinase inhibitor is selected from one of galardin or BB-94.
5 . The method of claim 1 wherein the calcitonin and the matrix metalloproteinase inhibitor are each administered to the subject orally.
6 . A method for treating a degenerative or an inflammatory disease in a subject comprising:
administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and
co-administering, as part of a combination therapy, a therapeutically effective amount of a tetracycline antibiotic to the subject.
7 . The method of claim 6 wherein the calcitonin is selected from the group consisting of human calcitonin, salmon calcitonin, eel calcitonin and elcatonin.
8 . The method of claim 6 wherein the calcitonin is salmon calcitonin.
9 . The method of claim 6 wherein the tetracycline antibiotic is doxycycline.
10 . The method of claim 6 wherein the calcitonin and the tetracycline antibiotic are each administered to the subject orally.
11 . A pharmaceutical composition for the treatment of a degenerative or an inflammatory disease comprising:
a first therapeutic agent that is calcitonin, in free or salt form;
a second therapeutic agent selected from the group consisting of a matrix metalloproteases inhibitor, an interleukin antagonist, an aggrecanase inhibitor, a tetracyline antibiotic, and a COX-2 inhibitor; and
a pharmaceutically acceptable excipient, carrier or diluent.
12 . The pharmaceutical composition of claim 11 wherein the second therapeutic agent is a matrix metalloproteases inhibitor.
13 . The pharmaceutical composition of claim 11 wherein the second therapeutic agent is an interleukin antagonist.
14 . The pharmaceutical composition of claim 11 wherein the second therapeutic agent is an aggrecanase inhibitor.
15 . The pharmaceutical composition of claim 11 wherein the second therapeutic agent is a tetracyline antibiotic.
16 . The pharmaceutical composition of claim 11 wherein the second therapeutic agent is a COX-2 inhibitor.
17 . The pharmaceutical composition of claim 11 wherein the second therapeutic agent is administered at a dosage no higher than 90% of the normal dosage for the second therapeutic agent when administered alone.
18 . The pharmaceutical composition of claim 11 , wherein the composition is an aqueous nasal spray.
19 . The pharmaceutical composition of claim 11 , wherein the composition is a solid dosage form.
20 . The pharmaceutical composition of claim 11 wherein the calcitonin is salmon calcitonin.